Inhibitor Therapeutics, Inc. (INTI) company profile
Close on Oct 19, 2026Market cap $19.06MP/E –Yield –
About Inhibitor Therapeutics
Pharmaceutical Preparations, SIC 2834
Inhibitor Therapeutics, Inc. is a pharmaceutical development company that focuses on repurposing approved active pharmaceutical ingredients to treat rare diseases, primarily targeting basal cell carcinoma nevus syndrome (Gorlin Syndrome). The company's lead development program centers on an oral formulation of itraconazole, an antifungal agent with anti-angiogenic properties that inhibit vascular growth supporting tumor proliferation. Its primary development candidate is a proprietary micronized and amorphous formulation developed to improve drug bioavailability and absorption for chronic disease management. The company currently operates without commercialized products, directing its activities toward preclinical and clinical evaluation to serve patients managed by dermatologists and Mohs micrographic surgeons.
The company operates primarily within the United States, targeting a domestic patient population of approximately 11,000 individuals with Gorlin Syndrome and an estimated prescriber base of 1,000 to 1,500 specialized Mohs surgeons. Inhibitor Therapeutics conducts its operations with two full-time employees and six part-time employees. It maintains its principal executive offices in Tampa, Florida.
Summary of the business section of Inhibitor Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Inhibitor Therapeutics, Inc.
- Founded
- 1992
- Headquarters
- Tampa, FL
- Address
- 4830 W. Kennedy Blvd., Suite 600 33609
- Phone
- (813) 766-2462
- Website
- inhibitortx.com
- Employees
- 2, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Cherry Bekaert LLP, Tampa, Florida
Stock & identifiers
- Ticker
- INTI
- Former tickers
- HPPI until May 9, 2019
- Exchange
- OTC
- IPO date
- Sep 13, 2013
- Shares outstanding
- 174M, Aug 14, 2026
- Public float
- $3.30M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1042418
- FIGI
- BBG000BW1GY2
- Share class FIGI
- BBG001SBC1N1
- EIN
- 54-1641133
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Francis E. Odonnell Jr | Chief Executive Officer, Director | 85,777,069 |
| James A. McNulty | Chief Financial Officer | 46,002,114 |
| Michelle Yanez | Director | 1,221,271 |
| Samuel P. Sears Jr | Director | 1,229,543 |
| Ronald E. Osman | Director | 23,554,985 |
| Michael Allen Jerman | Director | 180,411 |
| Niraj Vasisht | Director | 200,000 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $1.12M | $1.12M | $353.36K | $46 | – |
| FY2024 | $1.14M | $1.14M | $359.76K | $61 | – |
| FY2023 | $1.09M | $1.09M | $337.96K | $93 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Other | Total | vs. prior year |
|---|---|---|---|---|---|
| Francis E. O’Donnell Executive Chairman and Chief Executive Officer | $598.00K | $507.36K | $13.27K | $1.12M | -2% |
| James A. McNulty Interim Chief Financial Officer, Secretary and Treasurer | $200.00K | $138.49K | $24.09K | $362.57K | +1% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
Employees
Headcount reported in annual reports
“As of the date of this Report, we have two full-time employees and six part-time employees.”
Corporate history
Events identified from SEC filings
See a number that looks wrong?